Snapshot
Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5- [(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65:35.
The global Argatroban market will reach xxx Million USD in 2019 and CAGR xx% 2019-2024. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Argatroban by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
Argatroban Powder
Argatroban Injection
Company Coverage (Sales Revenue, Price, Gross Margin, Main Products etc.):
Pfizer
SANDOZ
GlaxoSmithKline
fresenius-kabi
Eagle Pharmaceuticals
Mitsubishi Tanabe Pharma
Teva Pharmaceutical Industries
WEST-WARD
Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):
Heparin-induced thrombocytopenia (HIT)
Percutaneous Coronary Intervention
Cerebral arterial thrombosis
Region Coverage (Regional Production, Demand & Forecast by Countries etc.):
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)